Related Experiment Video
Updated: Oct 18, 2025
04:59
Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
Published on: August 18, 2023
1.1K
Switching to the Dry-Powder Inhaler Easyhaler®: A Narrative Review of the Evidence
Federico Lavorini1, Jerzy Chudek2, Gabriella Gálffy3
1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Pulmonary Therapy
|September 28, 2021
Summary
Switching to the Easyhaler device can improve asthma and chronic obstructive pulmonary disease (COPD) control. This dry-powder inhaler is easy to use, promotes adherence, and reduces environmental impact.
Area of Science:
- Respiratory Medicine
- Pharmacology
- Medical Devices
Background:
- Asthma and COPD are significant global health issues.
- Suboptimal inhaler technique is a major barrier to effective disease control.
- Inhaler choice impacts treatment efficacy, patient adherence, and overall outcomes.
Purpose of the Study:
- To evaluate the effectiveness and patient acceptance of the Easyhaler device.
- To provide expert recommendations on inhaler selection for asthma and COPD.
- To highlight the benefits of dry-powder inhalers (DPIs) over metered-dose inhalers.
Main Methods:
- Review of evidence on inhaler use and effectiveness.
- Focus on the Easyhaler, a high/medium-high resistance DPI.
- Expert opinion from European physicians across multiple countries.
Main Results:
- Easyhaler use is linked to effective asthma and COPD control based on standard indicators.
- Patients widely accept the Easyhaler, finding it easy to learn and use.
- The device is associated with improved patient adherence and education.
Conclusions:
- Switching to the Easyhaler may enhance asthma and COPD management without increased risks.
- The Easyhaler facilitates correct inhaler use, drug selection, and device choice.
- Transitioning to DPIs like Easyhaler offers environmental and cost benefits by reducing greenhouse gas emissions.
Related Concept Videos
01:23Inhaled Medications
483
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
483
01:30Asthma-IV: Diagnostic and Management
2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
01:26COPD: Management Using Bronchodilators and Corticosteroids
478
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
478
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
452
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
452
01:22Drug Delivery: Miscellaneous Routes
544
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
544
01:24Asthma-III: Symptoms and Complications
2.7K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.7K